Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

被引：0
作者：
Licia Grazzi
Riccardo Giossi
Danilo Antonio Montisano
Mattia Canella
Marilena Marcosano
Claudia Altamura
Fabrizio Vernieri
机构：
[1] Fondazione IRCCS Istituto Neurologico Carlo Besta,Headache Center, Neuroalgology Department
[2] Grande Ospedale Metropolitano Niguarda,Poison Control Center and Clinical Pharmacology Unit
[3] Fondazione IRCCS Istituto Neurologico Carlo Besta,Department of Research and Clinical Development
[4] Università degli Studi di Milano,Department of Medical Biotechnology and Translational Medicine, Postgraduate School of Clinical Pharmacology and Toxicology
[5] Fondazione IRCCS Istituto Neurologico Carlo Besta,Neuroimmunology and Neuromuscular Diseases Unit
[6] Fondazione Policlinico Universitario Campus Bio-Medico,Department of Medicine and Surgery
[7] Università Campus Bio-Medico di Roma,undefined
来源：
The Journal of Headache and Pain | / 25卷
关键词：
Migraine; Erenumab; Galcanezumab; Fremanezumab; Onabotulinumtoxin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 188 条
  • [1] Natoli JL(2009)Global prevalence of chronic migraine: a systematic review Cephalalgia 30 599-609
  • [2] Manack A(2015)Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options Clin Med 15 344-350
  • [3] Dean B(2019)Current and emerging evidence-based treatment options in chronic migraine: a narrative review J Headache Pain 20 92-208
  • [4] Diener H-C(2021)Calcitonin gene-related peptide monoclonal antibodies Versus Botulinum Neurotoxin a in the Preventive treatment of chronic migraine: an adjusted Indirect Treatment Comparison Meta-Analysis Front Pharmacol 12 803-803
  • [5] Solbach K(2020)Botulinum Toxin in the Treatment of Headache Toxins (Basel) 12 201-1373
  • [6] Holle D(2019)Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine BMJ Open 9 793-1472
  • [7] Gaul C(2020)Impact of the botulinum-A toxin on prevention of adult migraine disorders J Integr Neurosci 19 1358-70
  • [8] Agostoni EC(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial Cephalalgia 30 1465-859
  • [9] Barbanti P(2011)OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program Headache 51 61-936
  • [10] Calabresi P(2011)OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine Neurology 77 851-803
12345678910